MannKind Q3 total revenue $51M, up 56% YoY; net income $2M GAAP

MANNKIND CORP

2023-Q3 EPS reported -$0.05 revenue$140,490,000

Total revenue $51.3M, +56% YoY; net income $2M (GAAP); non-GAAP net income $4M.
Tyvaso DPI royalties $20.2M, +225% YoY, driven by patient demand.
Afrezza net revenue $13.5M, +24% YoY on higher demand and price; V-Go down 18%.
Cash and investments $144.3M; R&D spending rose to $10M (vs $4.1M) on pipeline MNKD-101.
Commercial product gross margin improved to 78% from 69% YoY.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

MANNKIND CORP reported quarter ended September 30, 2023 results: revenue Total revenues of $51M, net income Net income of $2M.

Period: quarter ended September 30, 2023
Revenue: Total revenues of $51M
Net income: Net income of $2M
Result: reported results

Exact text from the filing

--- EX-99.1 EXHIBIT 99.1 MANNKIND CORPORATION REPORTS 2023 THIRD QUARTER FINANCIAL RESULTS Conference Call to Begin Today at 5:00 p.m. (ET) • 3Q 2023 Total revenues of $51M; +56% vs. 3Q 2022 • 3Q YTD 2023 Total revenues of $140M; +121% vs. 3Q YTD 2022 • 3Q 2023 Net income of $2M; Non-GAAP net income of $4M • 3Q 2023 Tyvaso DPI royalties of $20M;

View on SEC.gov

Browse all earnings releases →

MANNKIND CORP filing history →

Source: SEC EDGAR

accession 0000950170-23-060230

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.